Oxford BioTherapeutics Partners with Bristol Myers Squibb for Next-Gen T-Cell Therapies

Collaboration leverages OBT's OGAP®-Verify platform to advance novel oncology targets for solid tumors.

Apr. 9, 2026 at 1:33pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects in shades of gray and blue, conceptually representing the abstract concepts of cancer research, drug discovery, and pharmaceutical innovation.A refined, minimalist visual representation of the strategic partnership between Oxford BioTherapeutics and Bristol Myers Squibb to advance innovative cancer therapies.San Jose Today

Oxford BioTherapeutics (OBT), a clinical-stage oncology company, has entered a multi-year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next-generation T-cell engager therapies for solid tumors. OBT will leverage its proprietary OGAP®-Verify platform to identify novel, tumor-selective targets and generate T-cell engager molecules, while BMS will lead subsequent research, development, and commercialization activities.

Why it matters

This collaboration represents a significant validation of OBT's OGAP®-Verify platform and its ability to drive oncology innovation. It also reflects the growing confidence in OBT's capabilities to translate its scientific discoveries into development-ready therapeutic candidates. The partnership with a global leader in oncology like BMS will help accelerate the advancement of novel cancer therapies that have the potential to benefit patients.

The details

Under the terms of the agreement, OBT will receive an upfront payment and may be eligible for milestone payments and royalties on net sales of any commercialized products. OBT will be responsible for the design and delivery of development candidates, while BMS will lead subsequent research, development, and commercialization activities.

  • The collaboration was announced on April 9, 2026.

The players

Oxford BioTherapeutics (OBT)

A clinical-stage oncology company focused on the discovery and development of immuno-oncology and antibody-drug conjugate therapies enabled by its OGAP®-Verify platform.

Bristol Myers Squibb (BMS)

A global leader in oncology and a pharmaceutical company that will lead the research, development, and commercialization of the novel T-cell engager therapies discovered through the collaboration.

Got photos? Submit your photos here. ›

What they’re saying

“Collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies.”

— Christian Rohlff, Chief Executive Officer of OBT

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This collaboration highlights the growing importance of innovative target discovery and validation platforms like OBT's OGAP®-Verify in driving the development of next-generation cancer therapies. By combining OBT's scientific capabilities with BMS's expertise in translating oncology innovation into clinical and commercial success, the partnership has the potential to advance novel treatments that can make a meaningful difference for cancer patients.